Galapagos NV (NASDAQ:GLPG) Position Reduced by Rhumbline Advisers

Rhumbline Advisers trimmed its stake in shares of Galapagos NV (NASDAQ:GLPG) by 19.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,888 shares of the biotechnology company’s stock after selling 935 shares during the quarter. Rhumbline Advisers’ holdings in Galapagos were worth $98,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in GLPG. BNP Paribas Financial Markets boosted its stake in Galapagos by 45.9% during the 4th quarter. BNP Paribas Financial Markets now owns 8,972 shares of the biotechnology company’s stock valued at $247,000 after acquiring an additional 2,824 shares during the last quarter. GAMMA Investing LLC boosted its stake in Galapagos by 354.5% during the 1st quarter. GAMMA Investing LLC now owns 10,148 shares of the biotechnology company’s stock valued at $255,000 after acquiring an additional 7,915 shares during the last quarter. QRG Capital Management Inc. boosted its stake in Galapagos by 21.7% during the 4th quarter. QRG Capital Management Inc. now owns 10,455 shares of the biotechnology company’s stock valued at $288,000 after acquiring an additional 1,866 shares during the last quarter. Wealthedge Investment Advisors LLC bought a new position in Galapagos during the 4th quarter valued at $311,000. Finally, XTX Topco Ltd boosted its stake in Galapagos by 137.8% during the 4th quarter. XTX Topco Ltd now owns 19,833 shares of the biotechnology company’s stock valued at $545,000 after acquiring an additional 11,492 shares during the last quarter. 32.46% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen downgraded shares of Galapagos from a “hold” rating to a “sell” rating in a research report on Friday, April 25th. Five investment analysts have rated the stock with a sell rating and four have issued a hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus target price of $25.33.

Galapagos Stock Performance

Galapagos stock opened at $28.07 on Friday. The firm’s 50-day moving average is $27.50 and its 200-day moving average is $26.14. Galapagos NV has a 1 year low of $22.36 and a 1 year high of $31.23.

Galapagos (NASDAQ:GLPG) last posted its quarterly earnings results on Wednesday, April 23rd. The biotechnology company reported ($2.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($2.24). The firm had revenue of $97.33 million for the quarter, compared to the consensus estimate of $72.22 million. On average, equities research analysts forecast that Galapagos NV will post -1.6 earnings per share for the current year.

Galapagos Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.